SlideShare a Scribd company logo
Modelling exposure to pharmaceutical agents  J W Cherrie  1 , A T Gillies  2 , A Sleeuwenhoek  1 ,  M van Tongeren  1 , P McDonnell  3 , M Coggins  3 , S R Bailey  4   1. Institute of Occupational Medicine, UK. 2. Gillies Associates Ltd, UK. 3. National University of Ireland, Galway, Ireland. 4. GlaxoSmithKline, UK.
Summary… Background The model used for this study Adaptions for the pharmaceutical industry Results from a  “validation” exercise Discussion of future uses
Background… Powders are widely handled in the pharmaceutical industry Occupational inhalation exposure to these dusts may be harmful Some substances have exposure limits < 1µg/m 3   Within and between worker variability, and between plant variability make it difficult to reliably measure exposure with reasonable sampling effort Modelling exposure is one way to “leverage” scarce resources
The model… Originally developed for use in epidemiological research Use being extended into regulatory risk assessment Advanced REACH Tool (ART) Simple source-receptor model that relies on the assessor to select appropriate model parameters Validated in a number of previous situations, including mineral fibres, respirable dusts, PAH, benzene, solvents
Typical validation data…
The model… intrinsic properties  of the contaminant (ε i ),  the dustiness of a solid and the proportion of API in the mixture the way the material is  handled (h) ,  e.g. careful scooping of a powder the efficiency of  local controls  (1-η lv ).  These parameters are multiplied together
The model… passive or fugitive emission (ε p ) the fractional time the source was active ( t a )  the efficiency of respiratory protection (1- η ppe ) C  = (ε i   .  h .  (1 -η  lv  ) .  t a  + ε p  ) . (1 - η ppe  )
The model… Near and far-field Dispersion term dependant on the room ventilation and size C NF   = ( (ε i   .  h .  (1 - η lv  )) NF  .  t a,NF  + ε p,NF ) .  (1 - η ppe ) . d gv,NF   C FF   = ( (ε i   .  h .  (1 - η lv   )) FF  .  t a,FF  + ε p,FF ) . (1 - η ppe ) .  d gv,FF
Adaptions for the pharma industry Specific guidance for the industry
Validation… Three assessors (JWC, AS and PMcD) 27 scenarios with widely differing circumstances Assessors get written description of the scenario and then estimate the inhalation exposure level Blinded to the measurements
Results…
Discussion… Model appears useful for pharmaceutical powder handling  Gives agreement with measurements comparable to other circumstances Need better information on dustiness of powders This approach could be very useful for managing potential risks in the pharmaceutical industry

More Related Content

PPTX
What should we be doing to prevent occupational diseases from hazardous subst...
PPT
Air quality while cycling in Edinburgh
PDF
Estimation of consumer exposure to chemicals
PPT
6. Making it happen taking the smart approach
PPTX
5. Making a plan to eliminate risks - AIOH2013
PPTX
3. The Advanced REACH Tool (ART)
PPTX
Measuring and modeling dermal exposure – developments in Europe
PPT
The Advanced REACH Tool (ART) - an example
What should we be doing to prevent occupational diseases from hazardous subst...
Air quality while cycling in Edinburgh
Estimation of consumer exposure to chemicals
6. Making it happen taking the smart approach
5. Making a plan to eliminate risks - AIOH2013
3. The Advanced REACH Tool (ART)
Measuring and modeling dermal exposure – developments in Europe
The Advanced REACH Tool (ART) - an example

Viewers also liked (11)

PPTX
7. Final discussion and questions
PPTX
5. Making a plan to eliminate risks - SG
PDF
1. IOHA introduction
PDF
8. IOHA - where is it all going
PPT
Occupational Cancer Workshop presentation
PPT
5. ART example
PPTX
Low toxicity dusts: new concerns for old stuff.
PPTX
Risk assessment and management in britain
PPT
Mixed exposure to chemicals
PPTX
Health and safety regulatory trends in the UK semiconductor industry
PPTX
Asbestos exposure in asbestos insulation removal work at #asbestos2014
7. Final discussion and questions
5. Making a plan to eliminate risks - SG
1. IOHA introduction
8. IOHA - where is it all going
Occupational Cancer Workshop presentation
5. ART example
Low toxicity dusts: new concerns for old stuff.
Risk assessment and management in britain
Mixed exposure to chemicals
Health and safety regulatory trends in the UK semiconductor industry
Asbestos exposure in asbestos insulation removal work at #asbestos2014
Ad

Similar to Inhaled Particles presentation on exposure modelling (20)

PPTX
ndicators, Tracers and Surrogates - Why Use Them, Probability Analysis, Defin...
PPT
Dermal exposure measurement and modelling
DOCX
EDSP 360Lesson ComponentCriterionPoints PossiblePoints E.docx
PPT
Phase 1 protocol
PPTX
2. Tiered approaches
PPT
Monitoring dermal exposure to chemicals
PDF
EUGM 2014 | BEKELE | Adaptive Dose Finding Using Toxicity Probability Intervals
PDF
MPTI Talk
PPTX
L3- PERMISSIBLE THRESHOLD LIMITS.pptx
PPTX
Exposure assessment for occupational epidemiology part 1
PPTX
Exposure assessment for occupational epidemiology part 2
PPTX
assignment
PPTX
ISES Excellence in Exposure Science award
PPTX
cohort study;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
PPT
Cómo distinguir una investigación seria de una fraudulenta
PDF
Assignment On Design Of Experiment
PDF
Gemechu keneni(PhD) document
PPTX
EXPERIMENTAL EPIDEMIOLOGY
PPT
Farmacoepi Course Leiden 0210 Part 2
ndicators, Tracers and Surrogates - Why Use Them, Probability Analysis, Defin...
Dermal exposure measurement and modelling
EDSP 360Lesson ComponentCriterionPoints PossiblePoints E.docx
Phase 1 protocol
2. Tiered approaches
Monitoring dermal exposure to chemicals
EUGM 2014 | BEKELE | Adaptive Dose Finding Using Toxicity Probability Intervals
MPTI Talk
L3- PERMISSIBLE THRESHOLD LIMITS.pptx
Exposure assessment for occupational epidemiology part 1
Exposure assessment for occupational epidemiology part 2
assignment
ISES Excellence in Exposure Science award
cohort study;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;
Cómo distinguir una investigación seria de una fraudulenta
Assignment On Design Of Experiment
Gemechu keneni(PhD) document
EXPERIMENTAL EPIDEMIOLOGY
Farmacoepi Course Leiden 0210 Part 2
Ad

More from Retired (20)

PPTX
Asbestos exposure and risk in Britain today
PDF
Occupational health and hygiene research: A talk at the Scottish Parliament
PDF
Dermal exposure science: it’s not skin-deep
PPTX
Jim Vincent and inhalable dust
PDF
24,869
PPTX
A holistic approach to managing workplace exposure to solar UV
PPTX
Keynote presentation on Current and Future Trends in Exposure Science
PDF
The exposome and work
PDF
Control banding and beyond
PPTX
Exposure assessment for epidemiology
PPTX
What's the point of occupational exposure limits
PPTX
Interpretation of dermal exposure measurements and model outputs
PPTX
Modelling dermal exposure
PPTX
Measurement of dermal exposure - principles and methods
PPTX
Why is dermal exposure important?
PPTX
Skin exposure modelling and measurement - introduction
PPTX
Use of sensors in occupational exposure assessment
PDF
7. IOHA - the occupational exposome
PDF
6. IOHA - constructing the exposome
PDF
5. IOHA - biomarkers and the internal exposome
Asbestos exposure and risk in Britain today
Occupational health and hygiene research: A talk at the Scottish Parliament
Dermal exposure science: it’s not skin-deep
Jim Vincent and inhalable dust
24,869
A holistic approach to managing workplace exposure to solar UV
Keynote presentation on Current and Future Trends in Exposure Science
The exposome and work
Control banding and beyond
Exposure assessment for epidemiology
What's the point of occupational exposure limits
Interpretation of dermal exposure measurements and model outputs
Modelling dermal exposure
Measurement of dermal exposure - principles and methods
Why is dermal exposure important?
Skin exposure modelling and measurement - introduction
Use of sensors in occupational exposure assessment
7. IOHA - the occupational exposome
6. IOHA - constructing the exposome
5. IOHA - biomarkers and the internal exposome

Recently uploaded (20)

PPTX
Reading between the Rings: Imaging in Brain Infections
PPTX
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
PDF
Copy of OB - Exam #2 Study Guide. pdf
PDF
Transcultural that can help you someday.
PDF
The Digestive System Science Educational Presentation in Dark Orange, Blue, a...
PPTX
HYPERSENSITIVITY REACTIONS - Pathophysiology Notes for Second Year Pharm D St...
PPT
Rheumatology Member of Royal College of Physicians.ppt
PPTX
y4d nutrition and diet in pregnancy and postpartum
PDF
focused on the development and application of glycoHILIC, pepHILIC, and comm...
PPT
Infections Member of Royal College of Physicians.ppt
PPTX
Neoplasia III.pptxjhghgjhfj fjfhgfgdfdfsrbvhv
PPT
nephrology MRCP - Member of Royal College of Physicians ppt
PPTX
Effects of lipid metabolism 22 asfelagi.pptx
PDF
OSCE SERIES - Set 7 ( Questions & Answers ).pdf
PDF
OSCE SERIES ( Questions & Answers ) - Set 3.pdf
PPT
neurology Member of Royal College of Physicians (MRCP).ppt
PDF
Comparison of Swim-Up and Microfluidic Sperm Sorting.pdf
PPT
Dermatology for member of royalcollege.ppt
PPTX
Wheat allergies and Disease in gastroenterology
PPTX
Approach to chest pain, SOB, palpitation and prolonged fever
Reading between the Rings: Imaging in Brain Infections
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
Copy of OB - Exam #2 Study Guide. pdf
Transcultural that can help you someday.
The Digestive System Science Educational Presentation in Dark Orange, Blue, a...
HYPERSENSITIVITY REACTIONS - Pathophysiology Notes for Second Year Pharm D St...
Rheumatology Member of Royal College of Physicians.ppt
y4d nutrition and diet in pregnancy and postpartum
focused on the development and application of glycoHILIC, pepHILIC, and comm...
Infections Member of Royal College of Physicians.ppt
Neoplasia III.pptxjhghgjhfj fjfhgfgdfdfsrbvhv
nephrology MRCP - Member of Royal College of Physicians ppt
Effects of lipid metabolism 22 asfelagi.pptx
OSCE SERIES - Set 7 ( Questions & Answers ).pdf
OSCE SERIES ( Questions & Answers ) - Set 3.pdf
neurology Member of Royal College of Physicians (MRCP).ppt
Comparison of Swim-Up and Microfluidic Sperm Sorting.pdf
Dermatology for member of royalcollege.ppt
Wheat allergies and Disease in gastroenterology
Approach to chest pain, SOB, palpitation and prolonged fever

Inhaled Particles presentation on exposure modelling

  • 1. Modelling exposure to pharmaceutical agents J W Cherrie 1 , A T Gillies 2 , A Sleeuwenhoek 1 , M van Tongeren 1 , P McDonnell 3 , M Coggins 3 , S R Bailey 4 1. Institute of Occupational Medicine, UK. 2. Gillies Associates Ltd, UK. 3. National University of Ireland, Galway, Ireland. 4. GlaxoSmithKline, UK.
  • 2. Summary… Background The model used for this study Adaptions for the pharmaceutical industry Results from a “validation” exercise Discussion of future uses
  • 3. Background… Powders are widely handled in the pharmaceutical industry Occupational inhalation exposure to these dusts may be harmful Some substances have exposure limits < 1µg/m 3 Within and between worker variability, and between plant variability make it difficult to reliably measure exposure with reasonable sampling effort Modelling exposure is one way to “leverage” scarce resources
  • 4. The model… Originally developed for use in epidemiological research Use being extended into regulatory risk assessment Advanced REACH Tool (ART) Simple source-receptor model that relies on the assessor to select appropriate model parameters Validated in a number of previous situations, including mineral fibres, respirable dusts, PAH, benzene, solvents
  • 6. The model… intrinsic properties of the contaminant (ε i ), the dustiness of a solid and the proportion of API in the mixture the way the material is handled (h) , e.g. careful scooping of a powder the efficiency of local controls (1-η lv ). These parameters are multiplied together
  • 7. The model… passive or fugitive emission (ε p ) the fractional time the source was active ( t a ) the efficiency of respiratory protection (1- η ppe ) C = (ε i . h . (1 -η lv ) . t a + ε p ) . (1 - η ppe )
  • 8. The model… Near and far-field Dispersion term dependant on the room ventilation and size C NF = ( (ε i . h . (1 - η lv )) NF . t a,NF + ε p,NF ) . (1 - η ppe ) . d gv,NF   C FF = ( (ε i . h . (1 - η lv )) FF . t a,FF + ε p,FF ) . (1 - η ppe ) . d gv,FF
  • 9. Adaptions for the pharma industry Specific guidance for the industry
  • 10. Validation… Three assessors (JWC, AS and PMcD) 27 scenarios with widely differing circumstances Assessors get written description of the scenario and then estimate the inhalation exposure level Blinded to the measurements
  • 12. Discussion… Model appears useful for pharmaceutical powder handling Gives agreement with measurements comparable to other circumstances Need better information on dustiness of powders This approach could be very useful for managing potential risks in the pharmaceutical industry

Editor's Notes

  • #2: Thank you. This paper describes work that is being carried out collaboratively with the National University of Galway, Gillies Associates and GSK. I’d like to acknowledge the contributions of my coauthors.
  • #3: I’ll set out the background to the project, describe the model that we have been using for a number of years to reconstruct inhalation exposures to a wide range of substances and the adaption&apos;s we have made to apply it in the pharma industry to assess exposure to poowders, and the results of a validation exercise. We believe the methodology could be very useful for the industry in helping focus efforts on control and in maximizing the impact of any monitoring carried out. I’ll discuss these and other uses that the model has.
  • #6: Correlation on the log scale is 0.91 Bias Outliers
  • #10: Allow some variation to account for systems that are either better or worse than the indicated level Handling covered 4-orders of magnitude form careful weighing to sweeping with a broom Intrinsic emission not different
  • #12: Correlation between 0.88 and 0.97 (excluding the data &lt;100 micro-g/m3 reduced the correlation slightly) Note the scatter is partly due to error in the assessment and partly the error in the measurements, which are mostly based on small numbers. Two assessors with a slight positive bias and one with a negative bias. &lt;7% of the assessments are &lt;10% of the mean measurement
  • #13: ART Bayesian updating helps eliminate the bias